LicianPro

Inhibrx Biosciences, Inc. ·

INBX 8-K 2026-09-28

Inhibrx Biosciences, Inc. (INBX) 8-K dated 2026-09-28 — accession 0002007919-26-000050.

Inhibrx Biosciences, Inc. (INBX) is a biotechnology company listed on US.

Inhibrx Biosciences, Inc. filed a 8-K on 2026-09-28. Accession 0002007919-26-000050.

This 8-K covers: Reg FD disclosure (Item 7.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported INBX revenue for 2025-12-31 was $1.3M. Net income was -$140.1M. Revenue was up 550.0% from 2024-12-31 to 2025-12-31. INBX currently screens at market cap $1.28B.

Not investment advice. The INBX SEC hub lists recent forms. The stock page is the research view.

Open on SEC EDGAR

These filings as JSON? API free 100/day

Lician Pro $19.99/mo or $149/yr